Estudio integral de factores asociados a diabetes tipo 2 en México: protocolo

##plugins.themes.themeEleven.article.main##

Aldo Ferreira Hermosillo https://orcid.org/0000-0002-5159-9856
Rodolfo Rivas-Ruiz https://orcid.org/0000-0002-5967-7222
Ivonne Analí Roy-García https://orcid.org/0000-0002-1859-3866
Eduardo Antonio Ferat-Osorio https://orcid.org/0000-0001-5361-7854
Octavio Castro-Escamilla https://orcid.org/0000-0002-4061-4854
Keiko Taniguchi-Ponciano https://orcid.org/0000-0003-1623-7398
Daniel Marrero-Rodríguez https://orcid.org/0000-0001-5311-6654
Amelia Irene Rodríguez-Jiménez https://orcid.org/0009-0009-4439-6231
Patricia Pérez-Zataray https://orcid.org/0009-0004-9180-4801
Jose Luis Cevallos-Rivera https://orcid.org/0009-0009-1129-3076
Jorge A. Hernández-Casildo https://orcid.org/0000-0003-1692-9917
José Félix Saavedra-Ramírez https://orcid.org/0009-0008-4898-9598
Víctor G. Cruz-Morales https://orcid.org/0009-0006-1144-2607
Omar Livio Peralta-Méndez https://orcid.org/0009-0008-8530-4957
Alejandro M. Vargas-García https://orcid.org/0009-0002-2564-0496
Laura C. Bonifaz https://orcid.org/0000-0001-8482-5648
Rosana Pelayo https://orcid.org/0000-0003-3401-9757
Asa Christina Laurell https://orcid.org/0009-0009-0168-3089

Keywords

Diabetes Mellitus Tipo 2, Control Glucémico, Hemoglobina Glucada, Nefropatía Diabetica, Genes, Transcriptoma

Resumen

Una de las metas en el tratamiento de pacientes con diabetes tipo 2 (DT2) es la prevención de sus complicaciones. La mayoría de los estudios existentes han evaluado un número limitado y aislado de moléculas inflamatorias y factores metabólicos, y en pocas ocasiones se han considerado de manera conjunta variables clínicas y de estilo de vida.


El objetivo del presente estudio es describir el diseño del protocolo para la evaluación integral de los pacientes con DT2, considerando el control glucemico y sus complicaciones.


Se llevó a cabo un estudio transversal, observacional y multicéntrico en tres unidades de atención primaria en los estados de Coahuila, Jalisco y Veracruz. El descontrol glucémico se evaluará mediante la determinación de hemoglobina glucosilada, mientras que la nefropatía diabética se considerará a partir de alteraciones en la tasa de filtrado glomerular. Asimismo, se evaluarán parámetros clínicos y bioquímicos, estilo de vida, condición física, tipo de tratamiento, adherencia terapéutica y aspectos nutrimentales.


Adicionalmente, se realizará un análisis transcriptómico mediante RNA-Seq con el fin de identificar los genes que mejor estratifiquen y diferencien a los pacientes con descontrol glucémico, alteraciones metabólicas y nefropatía diabética, mediante análisis de componentes principales y curvas ROC basadas en la expresión relativa del RNA.


Para determinar los factores clínicos implicados en la asociación entre los perfiles moleculares y el descontrol glucémico, se desarrollarán modelos de regresión logística múltiple con el objetivo de identificar una huella molecular patológica característica de la enfermedad. 

Abstract 35 | PDF (Inglés) Downloads 30

Referencias

1. Furman D, Campisi J, Verdin E, Carrera-Bastos P, Targ S, Franceschi C, et al. Chronic inflammation in the etiology of disease across the life span. Nat Med. 2019;25(12):1822-32.
2. Basto-Abreu A, Lopez-Olmedo N, Rojas-Martinez R, Aguilar-Salinas CA, Moreno-Banda GL, Carnalla M, et al. Prevalence of prediabetes and diabetes in Mexico: ENSANUT 2022. Salud Publica Mex. 2023;65:s163-s8.
3. Francisco V, Pino J, Gonzalez-Gay MA, Mera A, Lago F, Gomez R, et al. Adipokines and inflammation: is it a question of weight? Br J Pharmacol. 2018;175(10):1569-79.
4. Dludla PV, Mabhida SE, Ziqubu K, Nkambule BB, Mazibuko-Mbeje SE, Hanser S, et al. Pancreatic beta-cell dysfunction in type 2 diabetes: Implications of inflammation and oxidative stress. World J Diabetes. 2023;14(3):130-46.
5. Mirza S, Hossain M, Mathews C, Martinez P, Pino P, Gay JL, et al. Type 2-diabetes is associated with elevated levels of TNF-alpha, IL-6 and adiponectin and low levels of leptin in a population of Mexican Americans: a cross-sectional study. Cytokine. 2012;57(1):136-42.
6. Halim M, Halim A. The effects of inflammation, aging and oxidative stress on the pathogenesis of diabetes mellitus (type 2 diabetes). Diabetes Metab Syndr. 2019;13(2):1165-72.
7. Alegre-Diaz J, Herrington W, Lopez-Cervantes M, Gnatiuc L, Ramirez R, Hill M, et al. Diabetes and Cause-Specific Mortality in Mexico City. N Engl J Med. 2016;375(20):1961-71.
8. Karstoft K, Pedersen BK. Exercise and type 2 diabetes: focus on metabolism and inflammation. Immunol Cell Biol. 2016;94(2):146-50.
9. Moghetti P, Bacchi E, Brangani C, Dona S, Negri C. Metabolic Effects of Exercise. Front Horm Res. 2016;47:44-57.
10. Dos Anjos D, Moreira BS, Kirkwood RN, Dias RC, Pereira DS, Pereira LSM. Effects of aerobic exercise on functional capacity, anthropometric measurements and inflammatory markers in diabetic elderly women. J Bodyw Mov Ther. 2017;21(3):509-16.
11. Laboratories ATSCoPSfCPF. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111-7.
12. Nolen-Doerr E, Crick K, Saha C, de Groot M, Pillay Y, Shubrook JH, et al. Six-Minute Walk Test as a Predictive Measure of Exercise Capacity in Adults with Type 2 Diabetes. Cardiopulm Phys Ther J. 2018;29(3):124-9.
13. Hasin Y, Seldin M, Lusis A. Multi-omics approaches to disease. Genome Biol. 2017;18(1):83.
14. Micheel CM, Nass SJ, Omenn GS. Evolution of Translational Omics: Lessons Learned and the Path Forward. Washington (DC)2012.
15. Dai X, Shen L. Advances and Trends in Omics Technology Development. Front Med (Lausanne). 2022;9:911861.
16. Chen ZZ, Gerszten RE. Metabolomics and Proteomics in Type 2 Diabetes. Circ Res 2020;126(11):1613-27.
17. Kwak SH, Park KS. Recent progress in genetic and epigenetic research on type 2 diabetes. Exp Mol Med. 2016;48(3):e220.
18. Tonyan ZN, Nasykhova YA, Danilova MM, Barbitoff YA, Changalidi AI, Mikhailova AA, et al. Overview of Transcriptomics Research on Type 2 Diabetes: Challenges and Perspectives. Genes (Basel). 2022;13(7).
19. Oropeza-Valdez JJ, Hernandez JCM, Jaime-Sanchez E, Lopez-Ramos E, Lara-Ramirez EE, Hernandez YL, et al. Transcriptome Analysis Identifies Oxidative Stress Injury Biomarkers for Diabetic Nephropathy. Arch Med Res. 2023;54(1):17-26.
20. School. UoEM. MODY Probability Calculator 2024 [Available from: https://www.diabetesgenes.org/exeter-diabetes-app/ModyCalculator .
21. da Silva Santos T, Fonseca L, Santos Monteiro S, Borges Duarte D, Martins Lopes A, Couto de Carvalho A, et al. MODY probability calculator utility in individuals' selection for genetic testing: Its accuracy and performance. Endocrinol Diabetes Metab. 2022;5(5):e00332.
22. Leighton E, Sainsbury CA, Jones GC. A Practical Review of C-Peptide Testing in Diabetes. Diabetes Ther. 2017;8(3):475-87.
23. Lopez-Carmona JM, Rodriguez-Moctezuma JR, Ariza-Andraca CR, Martinez-Bermudez M. [Lifestyle and metabolic control in patients with type 2 diabetes mellitus. Construct validation of IMEVID questionnaire]. Aten Primary. 2004;33(1):20-7.
24. Bernal-Orozco MF, Salmeron-Curiel PB, Prado-Arriaga RJ, Orozco-Gutierrez JF, Badillo-Camacho N, Marquez-Sandoval F, et al. Second Version of a Mini-Survey to Evaluate Food Intake Quality (Mini-ECCA v.2): Reproducibility and Ability to Identify Dietary Patterns in University Students. Nutrients. 2020;12(3).
25. Bernal-Orozco MF, Vizmanos-Lamotte B, Rodriguez-Rocha NP, Macedo-Ojeda G, Orozco-Valerio M, Roville-Sausse F, et al. Validation of a Mexican food photograph album as a tool to visually estimate food amounts in adolescents. Br J Nutr. 2013;109(5):944-52.
26. Nogues Solan X, Sorli Redo ML, Villar Garcia J. [Tools to measure treatment adherence]. An Internal Med. 2007;24(3):138-41.
27. Read MC. Validity of the 6-minute walk test and step test for evaluation of cardio respiratory fitness in patients with type 2 diabetes mellitus. J Exerc Nutrition Biochem. 2018;22(1):49-55.
28. Aguilar-Ramirez D, Alegre-Díaz J, Gnatiuc L, Ramirez-Reyes R, Wade R, Hill M, et al. Changes in the diagnosis and management of diabetes in Mexico City between 1998–2004 and 2015–2019. Diabetes Care. 2021;44(4):944–51.
29. Crosbie E, Otero Alvarez MG, Cao M, Vejar Renteria LS, Rodriguez E, Larrañaga Flota A, et al. Implementing front-of-pack nutrition warning labels in Mexico: important lessons for low- and middle-income countries. Public Health Nutrition. 2023 Oct 31;26(10):2149–61.
30. Pérez-Lozano DL, Camarillo-Nava VM, Juárez-Zepeda TE, Andrade-Pineda JE, Pérez-López D, Reyes-Pacheco JA, Lucho-Gutiérrez ZM, Carmona-Aparicio L. [Cost-effectiveness of treatment of type 2 diabetes mellitus in México. Rev Med Inst Mex Seguro Soc. 2023 Mar 1;61(2):172-180.
31. Picó-Guzmán FJ, Martínez-Montañez OG, Ruelas-Barajas E, Hernández-Ávila M. The estimated economic impact of cardiovascular and diabetes mellitus complications 2019-2028. Rev Med Inst Mex Seguro Soc. 2022 Dec 19;60(Suppl 2):S86-S95.
32. Shi J, Fan J, Su Q, Yang Z. Cytokines and Abnormal Glucose and Lipid Metabolism, Front in Endocrinol. 2019 Oct 30;10:1-16.